Who are Duo-Therapy with Sildenafil + Bosentan's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/duo-therapy-with-sildenafil-bosentan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Duo-Therapy with Sildenafil + Bosentan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duo-Therapy with Sildenafil + Bosentan (Duo-Therapy with Sildenafil + Bosentan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist. Area: Cardiovascular.

phase 3 Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist PDE-5; Endothelin receptor A and B Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Duo-Therapy with Sildenafil + Bosentan (Duo-Therapy with Sildenafil + Bosentan) — Johns Hopkins University. This combination therapy dilates pulmonary blood vessels through dual inhibition of phosphodiesterase-5 and endothelin-1 receptor signaling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duo-Therapy with Sildenafil + Bosentan TARGET	Duo-Therapy with Sildenafil + Bosentan	Johns Hopkins University	phase 3	Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist	PDE-5; Endothelin receptor A and B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: phosphodiesterase-5 inhibitor + endothelin receptor antagonist class)

Johns Hopkins University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duo-Therapy with Sildenafil + Bosentan — Competitive Intelligence Brief. https://druglandscape.com/ci/duo-therapy-with-sildenafil-bosentan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab